MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.19+0.09 (+8.18%)

Close on Nov 12, 2026Market cap $122.82MP/E –Yield –

MaxCyte price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

MaxCyte's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.4× to 3.9×, with a median of 1.8×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.7×	−0.2
2025	Dec 31, 2025	0.9×	−1.1
2024	Dec 31, 2024	2.1×	−0.0
2023	Dec 29, 2023	2.1×	−0.1
2022	Dec 30, 2022	2.2×	−1.7
2021	Dec 31, 2021	3.9×	–

Where these numbers come from

Parsed from the XBRL in MaxCyte's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MXCT.

Compare: MXCT vs OABI · MXCT vs FOXO · MXCT vs NRC · MXCT vs BIAF · MXCT vs CELU

Revenue growth-0.1% · median 3.4%

Operating margin-98.0% · median -115.9%

Net margin-81.4% · median -176.9%

Company	Revenue	Growth
NRC	$143.79M	+3.4%
OABI	$40.21M	+90.6%
MXCT	$34.37M	-0.1%
CELU	$18.67M	-58.1%
FOXO	$17.86M	+44.0%
BIAF	$5.53M	-18.5%

Company

Next earnings (est.): Mar 23, 2027, after close
Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 91
Held by institutions: 61.3%
Auditor: CohnReznick LLP
SEC CIK: 1287098

Advertisement
300 × 250

See a number that looks wrong?